<DOC>
	<DOCNO>NCT01263171</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , oxaliplatin , leucovorin , fluorouracil , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Giving chemotherapy surgery may make tumor small reduce amount normal tissue need remove . Giving chemotherapy surgery may kill tumor cell remain surgery . PURPOSE : This phase II trial study give oxaliplatin , leucovorin , fluorouracil together , radiation therapy surgery treat patient rectal cancer remove surgery .</brief_summary>
	<brief_title>Oxaliplatin , Leucovorin , Fluorouracil Before After Radiation Therapy Surgery Treating Patients With Rectal Cancer That Can Be Removed Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - To assess feasibility introduce 8 week neoadjuvant oxaliplatin fluorouracil follow radiotherapy immediate surgical resection patient resectable adenocarcinoma rectum . Secondary - Determine feasibility achieve dose intensity chemotherapy radiotherapy patient . - Determine safety , term NCI CTCAE version 4 toxicity , include postoperative complication rate ( 30 day postoperatively ) , late toxicity assessment 1 year follow surgery , patient . - Determine active neoadjuvant chemotherapy , term stag rectal cancer , local recurrence-free , distant metastasis-free , overall survival 1 year follow surgery patient . Neoadjuvant therapy : Patients receive oxaliplatin leucovorin ( L-leucovorin leucovorin calcium ) IV 2 hour day 1 fluorouracil IV 46 hour day 1-2 . Treatment repeat every 2 week 4 course absence disease progression unacceptable toxicity . Radiotherapy/Surgery : Beginning 1 week completion chemotherapy , patient undergo radiotherapy , follow surgical resection primary tumor , within 7-14 day completion radiotherapy . Between 6-8 week follow surgery , patient begin adjuvant therapy . Adjuvant therapy : Patients receive oxaliplatin leucovorin ( L-leucovorin leucovorin calcium ) IV 2 hour day 1 fluorouracil IV 46 hour day 1-2 . Treatment repeat every 2 week 8 course absence disease progression unacceptable toxicity . Blood biopsy specimen collect baseline periodically translational research study . After completion study therapy , patient follow periodically 1 year . Peer Reviewed Funded Endorsed Cancer Research UK .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histopathologically confirm rectal adenocarcinoma meeting follow criterion : Inferior aspect tumor &gt; 4 cm anal verge digital examination pelvic MRI scan Superior aspect tumor high anterior aspect S1/S2 interspace pelvic MRI scan Mesorectal fascia threaten involve ( tumor &gt; 1 mm mesorectal fascia ) Primary tumor meet 1 follow criterion : T3ab ( mesorectal primary tumor invasion see ≤ 5 mm beyond muscularis propria ) presence 1 following : Extramural vascular invasion Mesorectal lymph node ( ) /tumor deposit ( ) irregular border mixed signal intensity Any T3c ( primary tumor invasion see &gt; 5 mm beyond muscularis propria ) T4a ( invasion visceral peritoneum tumor component peritoneal reflection ) Low tumor involve levator ani ( &gt; 1 mm gap tumor levator ani ) anal sphincter No evidence distant metastasis stage T4b cancer invasion adjacent organ structure Must measurable disease baseline visit Impending rectal obstruction permit relieved nonfunctioning ileostomy colostomy No disease threaten mesorectal fascia ( disease ≤ 1 mm mesorectal fascia whether primary tumor , extramural vascular invasion , tumor deposit irregular border mixed signal intensity ) PATIENT CHARACTERISTICS : ECOG performance status 01 Hemoglobin ≥ 9 g/dL WBC ≥ 3 x 10^9/L Absolute neutrophil count ≥ 1.5 x10^9/L Platelet count ≥ 100 x10^9/L Total bilirubin ≤ 1.5 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 5 x ULN AST ALT ≤ 2.5 x ULN Creatinine clearance ≥ 50 mL/min Magnesium calcium normal Candidate systemic therapy , opinion primary oncologist No known significant impairment intestinal absorption ( e.g. , chronic diarrhea , inflammatory bowel disease ) No evidence establish acute ischemic heart disease ( e.g. , leave bundle branch block , pathological qwaves , ST elevation , STsegment depression ) normal clinical cardiovascular assessment ECG No enlarge pelvic sidewall lymph nod No severe local bowel symptom tenesmus irregularity frequency bowel habit preclude accurate assessment diarrhea No pelvic sepsis No uncontrolled infection Not pregnant nursing Fertile patient must use effective contraception treatment 6 month completion treatment No prior current malignant disease , judgement treat investigator , likely interfere study treatment assessment response No clinically significant cardiovascular disease , include follow within past year : Myocardial infarction Unstable angina Symptomatic congestive heart failure Serious uncontrolled cardiac arrhythmia No history interstitial lung disease ( e.g. , pneumonitis pulmonary fibrosis evidence interstitial lung disease ) PRIOR CONCURRENT THERAPY : No prior pelvic radiotherapy No metallic colon stent rectal stent situ More 30 day since prior chemotherapy , radiotherapy , hormonal treatment , antibody therapy , immunotherapy , gene therapy , vaccine therapy , angiogenesis inhibitor , matrix metalloproteinase inhibitor , thalidomide , antiVEGF/Flk1 monoclonal antibody , experimental drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>adenocarcinoma rectum</keyword>
	<keyword>stage IIIB rectal cancer</keyword>
	<keyword>stage IIIC rectal cancer</keyword>
</DOC>